<DOC>
	<DOCNO>NCT02818309</DOCNO>
	<brief_summary>Lesogaberan may use Chinese GERD patient partial response PPI .</brief_summary>
	<brief_title>Lesogaberan Chinese Patients With Refractory Reflux Symptoms</brief_title>
	<detailed_description>To test efficacy safety lesogaberan .</detailed_description>
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Lesogaberan</mesh_term>
	<criteria>Inclusion criterion 1 . Provision inform consent prior study specific procedure . 2 . Male female . Females childbearing potential must use highly effective contraceptive method least previous 3 month . 3 . Age 2070 year , inclusive . 4 . Body Mass Index ( BMI ) 18.5 35.0 kg/m2 , inclusive . 5 . Have least 6 month history Gastroesophageal reflux disease ( GERD ) symptom ( need consecutive ) endoscopy document erosive esophagitis within 4 month . 6 . Continuously treat last 8 week enrolment daily optimise unchanged standard dose proton pump inhibitor ( PPI ) therapy , esomeprazole 40 mg , lansoprazole 30 mg , dexlansoprazole 60 mg , rabeprazole 30 mg pantoprazole 40 mg. 7 . Able read write local language use ediary device . 8 . To eligible screening phase patient must report Reflux Symptom Questionnaire 7 day recall ( RESQ7 ) use 7 day recall symptom , minimum 3 day rating least moderate intensity least 1 follow item ; burn feel behind breastbone unpleasant movement material upwards stomach . 9 . To eligible randomisation patient must record Reflux Symptom Questionnaire electronic diary ( RESQeD ) last 7 day randomisation , minimum 3 day symptom intensity least moderate 1 2 item ( burn feel behind breastbone unpleasant movement material upwards stomach ) , combination item ( eg , 1 day 1 item 2 day ) . Exclusion criteria 1 . Patients experience GERD symptom improvement PPI treatment . 2 . Unstable clinically significant cardiovascular ( ischemic heart disease , congestive heart failure , arrhythmia ) , respiratory ( chronic obstructive pulmonary disease ) , hepatic ( AST ALT total bilirubin &gt; upper limit normal ) , renal ( &gt; 1.5 mg/dL ) , metabolic ( serum potassium magnesium &lt; low reference range ) , psychiatric ( major depression , schizophrenia ) , gastrointestinal esophageal disorder besides GERD ( peptic ulcer , eosinophilic esophagitis ) . 3 . Current neurological disorder include nerve compression syndrome . Patients well control migraine headache disorder could include . 4 . History clinically significant orthostatic reaction syncope . 5 . History heart disease ( include ischemic heart disease , congestive heart failure , cardiac arrhythmia , congenital long QT syndrome ) , current sign symptom heart disease , patient clinically significant ECG abnormality QTcF &gt; 450 m determine investigator . 6 . History , current malignant disease ( radically treat basal cell cancer allow ) . 7 . History clinically significant electrolyte imbalance . 8 . History severe allergic hypersensitivity reaction ( Stevens Johnson syndrome , anaphylactic shock , angioedemaurticaria ) . 9 . Using concomitant drug could potentially interfere pharmacodynamic effect lesogaberan ( baclofen supplement contain GABA ) , alter gastrointestinal symptom ( type2 histamine receptor agonist ) cause damage mucosal line gastrointestinal tract ( nonsteroidal antiinflammatory drug acetylsalicylic acid &gt; 162 mg/day ) . 10 . Prior surgery upper GI tract 11 . Pregnant breastfeeding female</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>